Multiple ovulations, ovarian epithelial inclusion cysts, and it'SMAD two!

Endocrinology

Volumn 148, Issue 8, 2007, Pages 3591-3594

  Kumar, T Rajendra ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD2 PROTEIN; SMAD3 PROTEIN;

CELL PROLIFERATION; DISEASE MODEL; ENZYME PHOSPHORYLATION; NONHUMAN; OVARY CANCER; OVARY CELL; OVARY CYST; OVARY DEVELOPMENT; OVARY FUNCTION; OVULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SHORT SURVEY; TRANSGENIC MOUSE;

ANIMALS; EPITHELIAL CELLS; FEMALE; HUMANS; OVARIAN CYSTS; OVARIAN NEOPLASMS; OVULATION; SMAD2 PROTEIN;

EID: 34547113523     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0574     Document Type: Short Survey

References (41)

1. Cotran R, Kumar V, Collins T 1999 Robbins pathologic basis of disease. 6th ed. Philadelphia: W.B. Saunders Co.
2. Scott M, McCluggage WG 2006 Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol 21:81-92
3. Christie M, Oehler MK 2006 Molecular pathology of epithelial ovarian cancer. J Br Menopause Soc 12:57-63
4. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE 2002 Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62
5. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF 2000 Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585-591
6. Lowry S, Russell H, Hickey I, Atkinson R 1991 Incessant ovulation and ovarian cancer. Lancet 337:1544-1545
7. Risch HA 1998 Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774-1786
8. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC 2003 Ovulation and risk of epithelial ovarian cancer. Int J Cancer 104:228-232
9. Bristol-Gould SK, Hutten CG, Sturgis C, Kilen SM, Mayo KE, Woodruff TK 2005 The development of a mouse model of ovarian endosalpingiosis. Endocrinology 146:5228-5236
10. Choi JH, Wong AS, Huang HF, Leung PC 2007 Gonadotropins and ovarian cancer. Endocr Rev 28:440-461
11. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW 2007 Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 16:30-35
12. Burdette JE, Oliver RM, Ulyanov V, Kilen SM, Mayo KE, Woodruff TK 2007 Ovarian epithelial inclusion cysts in chronically superovulated CD1 and Smad2 dominant-negative mice. Endocrinology 148:3595-3604
13. McMullen ML, Cho BN, Yates CJ, Mayo KE 2001 Gonadal pathologies in transgenic mice expressing the rat inhibin α-subunit. Endocrinology 142:5005-5014
14. Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW 2004 Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol Cell Endocrinol 225:29-36
15. Pangas SA, Woodruff TK 2000 Activin signal transduction pathways. Trends Endocrinol Metab 11:309-314
16. Gaddy-Kurten D, Tsuchida K, Vale W 1995 Activins and the receptor serine kinase superfamily. Recent Prog Horm Res 50:109-129
17. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, Petraglia F, Yu J, Plotsky P, Spiess J, Rivier J 1988 Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44:1-34
18. Xu L 2006 Regulation of Smad activities. Biochim Biophys Acta 1759:503-513
19. Massague J, Gomis RR 2006 The logic of TGFβ signaling. FEBS Lett 580:2811-2820
20. Kaivo-oja N, Jeffery LA, Ritvos O, Mottershead DG 2006 Smad signalling in the ovary. Reprod Biol Endocrinol 4:21
21. Woodruff TK 2002 Role of inhibins and activins in ovarian cancer. Cancer Treat Res 107:293-302
22. Narula A, Kilen S, Ma E, Kroeger J, Goldberg E, Woodruff TK 2002 Smad4 overexpression causes germ cell ablation and leydig cell hyperplasia in transgenic mice. Am J Pathol 161:1723-1734
23. Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, Hanash S, Katabuchi H, Ellenson LH, Fearon ER, Cho KR 2005 Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 11:2123-2131
24. Tan OL, Hurst PR, Fleming JS 2005 Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer? J Pathol 205:483-490
25. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL 2006 Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 247:4-21
26. La Vecchia C, Franceschi S, Gallus G, Decarli A, Liberati A, Tognoni G 1983 Incessant ovulation and ovarian cancer: a critical approach. Int J Epidemiol 12:161-164
27. Fleming JS, McQuillan HJ, Millier MJ, Beaugie CR, Livingstone V 2007 E-cadherin expression and bromodeoxyuridine incorporation during development of ovarian inclusion cysts in age-matched breeder and incessantly ovulated CD-1 mice. Reprod Biol Endocrinol 5:14
28. Tomic D, Miller KP, Kenny HA, Woodruff TK, Hoyer P, Flaws JA 2004 Ovarian follicle development requires Smad3. Mol Endocrinol 18:2224-2240
29. Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC, Matzuk MM 1999 Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 13:851-865
30. Matzuk MM, DeMayo FJ, Hadsell LA, Kumar TR 2003 Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice. Biol Reprod 69:338-346
31. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC 2007 Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 313:133-145
32. Rangarajan A, Weinberg RA 2003 Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3:952-959
33. Hahn WC, Weinberg RA 2002 Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341
34. Hanahan D, Weinberg RA 2000 The hallmarks of cancer. Cell 100:57-70
35. Chamorro MN, Schwartz DR, Vonica A, Brivanlou AH, Cho KR, Varmus HE 2005 FGF-20 and DKK1 are transcriptional targets of β-catenin and FGF-20 is implicated in cancer and development. EMBO J 24:73-84
36. Peltoketo H, Allinen M, Vuosku J, Kujala S, Lundan T, Salminen A, Winqvist R, Vainio S 2004 Characterization and expression of the human WNT4; lack of associated germline mutations in high - to moderate - risk breast and ovarian cancer. Cancer Lett 213:83-90
37. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, Hedin L, Sundfeldt K 2003 Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β. Br J Cancer 89:1298-1304
38. Cheng W, Liu J, Yoshida H, Rosen D, Naora H 2005 Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11:531-537
39. Esposito G 2007 Complementary techniques: laser capture microdissection-increasing specificity of gene expression profiling of cancer specimens. Adv Exp Med Biol 593:54-65
40. Nambiar PR, Boutin SR, Raja R, Rosenberg DW 2005 Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia. Vet Pathol 42:735-752
41. Luzzi VI, Holtschlag V, Watson MA 2005 Gene expression profiling of primary tumor cell populations using laser capture microdissection, RNA transcript amplification, and GeneChip microarrays. Methods Mol Biol 293:187-207